Status:

COMPLETED

Mitochondrial Dysfunctions Driving Insulin Resistance

Lead Sponsor:

Rigshospitalet, Denmark

Collaborating Sponsors:

University of Copenhagen

Conditions:

Mitochondrial Myopathies

Mitochondrial Diseases

Eligibility:

All Genders

18+ years

Brief Summary

The overarching aim of this observational study is to characterize muscle mitochondrial defects in individuals harboring pathogenic mitochondrial DNA (mtDNA) mutations associated with an insulin-resis...

Detailed Description

Background: Peripheral insulin resistance is a major risk factor for metabolic diseases such as type 2 diabetes. Skeletal muscle accounts for the majority of insulin-stimulated glucose disposal, hence...

Eligibility Criteria

Inclusion

  • Eligibility criteria for individuals with pathogenic mtDNA mutations
  • Inclusion criteria:
  • Known m.3243A\>G mutation in the MT-TL1 gene encoding the mitochondrial leucyl-tRNA 1 gene
  • Other known mtDNA point mutations
  • Exclusion criteria:
  • Use of antiarrhythmic medications or other medications which, in the opinion of the investigators, have the potential to affect outcome measures.
  • Diagnosed severe heart disease, dysregulated thyroid gland conditions, or other dysregulated endocrinopathies, or other conditions which, in the opinion of the investigators, have the potential to affect outcome measures.
  • Pregnancy
  • Eligibility criteria for controls
  • Exclusion criteria:
  • Current and regular use of antidiabetic medications or other medications which, in the opinion of the investigators, have the potential to affect outcome measures.
  • Diagnosed heart disease, symptomatic asthma, liver cirrhosis or -failure, chronic kidney disease, dysregulated thyroid gland conditions or other dysregulated endocrinopathies, or other conditions which, in the opinion of the investigators, have the potential to affect outcome measures
  • Daily use of tobacco products
  • Excessive alcohol consumption
  • Pregnancy

Exclusion

    Key Trial Info

    Start Date :

    October 20 2023

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    December 20 2024

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT06080581

    Start Date

    October 20 2023

    End Date

    December 20 2024

    Last Update

    June 22 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Rigshospitalet

    Copenhagen, Denmark, Denmark, 2100

    Mitochondrial Dysfunctions Driving Insulin Resistance | DecenTrialz